-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 12, 2021, Medivir announced that its topical histone deacetylase (HDAC) inhibitor remetinostat has obtained positive results in a phase 2 clinical trial for adjuvant treatment of patients with basal cell carcinoma (BCC)
BCC is a common skin cancer, and the current main treatment is surgical resection
Among the 33 tumors analyzed in the final analysis, the overall response rate (ORR) was 69.
▲Remetinostat molecular structure (picture source: PubChem)
Previously, a dose-escalation phase 2 trial of the drug in patients with mycosis fungal skin T-cell lymphoma (MF-CTCL) showed that the severity of skin lesions in patients decreased, with an objective response rate (ORR) of up to 40% At the highest dose, the severity of itching in 80% of patients was clinically significantly reduced
(The original text has been deleted)
Reference materials:
[1] Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research.
[2] Kilgour, JM, et, al.
[3] A New Type of Gel Shows Promise Against Common Type of Skin Cancer.